Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia

Table 2 Average relapse rate during follow-up period

	Period from index date to the end of F/U, among patients who initiated LAI after index date (N = 2222)
	From index date to LAI initiation	From LAI initiation to end of F/U	P value
Relapse rate (PPPM)^a,b	0.109	0.073	< 0.0001
Hospitalization rate (PPPM)	0.091	0.058	< 0.0001
ER rate (PPPM)	0.017	0.015	0.2552

ER emergency room, F/U follow-up, LAI long-acting injectable, PPPM per patient per month
^aRelapse is defined as hospitalization or ER visits with a diagnosis of schizophrenia as primary or secondary diagnosis, assessed from index date to the end of follow-up (F/U) period
^bRate in PPPM is calculated as “number of events within the specific period” divided by “duration of the specific period in months” for a given patient

ISSN: 1471-244X